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Secretion of the proinflammatory cytokines, interleukin
(IL)-1 and IL-18, usually requires two signals. The first, due to
microbial products such as lipopolysaccharide, initiates tran-
scription of the cytokine genes and accumulation of the precur-
sor proteins.Cleavage and secretionof the cytokines ismediated
by caspase-1, in association with an inflammasome containing
Nalp3,which can be activated by binding of extracellularATP to
purinergic receptors. We show that treatment of macrophages
with ATP results in production of reactive oxygen species
(ROS), which stimulate the phosphatidylinositol 3-kinase
(PI3K) pathway and subsequent Akt and ERK1/2 activation.
ROS exerts its effect through glutathionylation of PTEN (phos-
phatase and tensin homologue deleted from chromosome 10),
whose inactivation would shift the equilibrium in favor of PI3K.
ATP-dependent ROSproduction andPI3K activation also stim-
ulate transcription of genes required for an oxidative stress
response. In parallel, ATP-mediated ROS-dependent PI3K is
required for activation of caspase-1 and secretion of IL-1 and
IL-18. Thus, an increase in ROS levels in ATP-treated macro-
phages results in activation of a single pathway that promotes both
adaptation to subsequent exposure to oxidants or inflammation,
and processing and secretion of proinflammatory cytokines.
The inflammatory mediator, extracellular ATP, binds to P2
purinergic receptors that are expressed on a wide spectrum of
cell types, including macrophages and epithelial cells (1). The
P2 receptors can be classified into two families, the P2X ligand-
gated cation channels and the G protein-coupled P2Y recep-
tors. The only known physiological ligand for P2X receptors is
extracellular ATP, whereas remaining P2Y receptors can inter-
act with ATP and other nucleotides such as UTP, UDP, and
ADP (1).
P2X7 plays a key role in cells from the immune system.
Depending on the cell type, treatment with ATP leads to per-
meabilization of the plasma membrane, cell death, cell prolif-
eration, shedding of cell-adhesionmolecules, killing of intracel-
lular pathogens, and secretion of mature IL-12 and IL-18
(2–4).Whereas the pathways leading from P2X7 ligation to the
different cell responses remain to be characterized in most
cases, ATP has been shown to activate various cell signaling
mediators, including ERK1/2, PI3K, calcium fluxes, and p38
MAP kinases (5–8).
The proinflammatory cytokines IL-1 and IL-18 play an
important role in fever, septic shock, and inflammatory disease
(9). In macrophages, their production and secretion are there-
fore tightly controlled, requiring typically two separate signals
(10, 11). Priming of macrophages with pathogen-associated
molecular patterns such as LPS is sufficient to stimulate synthe-
sis of pro-IL-1, but secretion of the mature cytokine requires
its cleavage by caspase-1. Caspase-1, in turn, is expressed con-
stitutively as an inactive pro-caspase-1. Cleavage and activation
of caspase-1 takes place in association with protein complexes
termed inflammasomes, of which there are two types. The
inflammasome that is activated after P2X7 ligation contains the
adaptormoleculeASC (apoptosis-associated speck-like protein
containing a CARD), cardinal, and the NOD-like receptor fam-
ily member, Nalp3 (also known as cryopyrin). The Nalp3
inflammasome can be activated by “danger signals” (danger-
associated molecular patterns or DAMP) released from
stressed or infected eucaryotic cells, such as ATP or uric acid
crystals (10, 11), which by themselves do not promote synthesis
of the cytokines. LPS priming can increase the efficiency of
ATP-mediated caspase-1 activation, but is not required (12,
13). Thus, a pathogenmust both express a pathogen-associated
molecular pattern capable of driving cytokine synthesis, and be
viewed as potentially dangerous to the host organism, for
mature IL-1 and IL-18 to be secreted efficiently.
P2X7 ligation can lead to pore formation and cytosolic K
depletion, and depleting Kwith ionophores without extracel-
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lular ATP treatment results in activation of caspase-1 and
secretion of IL-1 and IL-18 in macrophages that had been
primed with LPS (2, 10). Several pathogens that produce toxins
that promote host-cell K efflux can also activate the inflam-
masome, in the absence of a second signal from danger-associ-
ated molecular patterns. It was thus proposed that K deple-
tion, which may be detected by Nalp3, may be a common
mechanism used by different danger-associated molecular pat-
terns and pathogens to activate the inflammasome (11, 14).
Nonetheless, K effluxes have not been reported in cells stim-
ulated with uric acid crystals, which must be endocytosed to
activate the inflammasome (15), and somepathogen-associated
molecular patterns such as peptidoglycan and bacterial mRNA
may activate the Nalp3 inflammasome after being detected in
the cytosol, making it likely that a decrease in cytosolic K
concentrations may have its effect on Nalp3 indirectly (10), or
macrophages may also use other pathways to transmit signals
from danger-associated molecular patterns such as ATP to the
inflammasome.
We have therefore addressed the possibility that reactive
oxygen species (ROS) produced afterATP treatment of primary
macrophages may stimulate caspase-1 activation and process-
ing of IL-1 and IL-18. The production of ROS such as H2O2
was long considered as an undesirable consequence of aerobic
respiration, being associated with diseases as diverse as aging,
cancer, and neurodegenerative disease (16). More recently,
however, it has become clear that H2O2 is also a physiological
mediator in cell signaling pathways involved in differentiation,
proliferation, migration, and cytokine secretion (17, 18). Signif-
icantly, an ROS response in psychologically stressed mice leads
to caspase-1 activation, secretion of IL-1, and up-regulation of
plasma IL-18 (19).
Given the ability of ROS to activate PI3K and ERK1/2 (20,
21), we also investigated whether ATP-dependent ROS pro-
duction could activate PI3K and its downstreammediators.We
found that in addition to activating PI3K, probably by inactivat-
ing PTEN (phosphatase and tensin homologue deleted from
chromosome 10) through glutathionylation, ATP-mediated
ROS production can activate ERK1/2 and, subsequently,
caspase-1, which is required for IL-1 and IL-18 processing. In
parallel, the PI3K pathway is involved in stimulating transcrip-
tion of genes involved in glutathione synthesis and an oxidative
stress response.
EXPERIMENTAL PROCEDURES
Cells and Reagents—ADP, ATP, BzATP, oxATP, UTP,
LY-294002, wortmannin, and diphenyleneiodonium chloride
(DPI) were purchased from Sigma, whereas PD98059 was from
Calbiochem (La Jolla, CA). Z-YVAD-fmk was from Biovision
(Mountain View, CA). The antibodies used for Western blot-
ting were anti-p44/p42 MAPK (Thr202/Tyr204), anti-rabbit
p44/p42 and anti-p38 (Tyr(P)180/182), pAKT (Thr308), from
Cell Signaling Technology (Beverly, MA); and Akt1 (C-20),
from Santa Cruz Biotechnology (Santa Cruz, CA). The alveolar
macrophages, NR8383, were isolated from Sprague-Dawley
rats (22). NR8383 macrophages were maintained in F-12K
medium (Invitrogen) supplemented with 15% heat-inactivated
fetal bovine serum (Invitrogen), 100 units/ml penicillin, and
100g/ml streptomycin at 37 °C in a humidified atmosphere of
5% CO2.
Measurement of ROS Production by FACS and Fluorescence
Microscopy—NR8383 cells were treated with different agonists
and inhibitors followed by addition of 2,7-dichlorofluorescein
(DCF) (Molecular Probes, Eugene, OR) for 5 min. The samples
were analyzed by FACS with a Guava EasyCyte (Hayward, CA)
or a Leica epifluorescence microscope (Mannheim, Germany)
at 500 nm.
Immunoblotting for Akt and ERK1/2 Phosphorylation—Pro-
teins from lysed cells were analyzed on a SDS-PAGE 4–20% gel
(Bio-Rad) and then transferred to a polyvinylidene difluoride
membrane (Bio-Rad). Blots were blocked for 1 h with 5% (w/v)
nonfat driedmilk inTBST. Themembranewas incubated over-
night at 4 °C with specific antibodies and then incubated
again with the corresponding conjugated anti-mouse, anti-rab-
bit, or anti-goat IgG horseradish peroxidase. Immunoreactive
proteins were detected with the ECL Western blotting detec-
tion kit (Amersham Biosciences).
Intracellular Staining for ERK1/2 Phosphorylation—NR8383
cells were pretreated with different agonists or inhibitors and
centrifuged for 10 min at 600 g. The pellet was resuspended
in ice-coldmethanol and then incubated for 30min at 4 °C. The
samples were rinsedwith incubation buffer (0.5% bovine serum
albumin in phosphate-buffered saline) and then incubated for
1 h at room temperature in incubation buffer with the primary
Ab. After rinsing, the samples were treated for 30 min with the
secondary fluorescein isothiocyanate-conjugated Ab (Santa
Cruz Biotechnology). The samples were then rinsed with phos-
phate-buffered saline and analyzed by FACS with the Guava
EasyCyte.
Immunoprecipitation for PTEN Glutathionylation—Ten
million NR8383 cells were lysed for 30 min on ice with a lysis
buffer containing 50 mM Hepes, 150 mM NaCl, 50 mM -glyc-
erophosphate, 1 mM sodium orthovanadate, 10 mM sodium
pyrophosphate, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluo-
ride, 100 mM sodium fluoride, 5 mMGSH, 10 M diethylenetri-
aminepentaacetic acid, 0.5%Nonidet-40, 1%TritonX-100, 10%
glycerol, 10 ng/ml leupeptin, and 10 ng/ml aprotinin, pH 7.4.
The lysates were then centrifuged at 10,000 g for 10 min and
the proteins were collected. Five hundred micrograms of pro-
tein was incubated with anti-PTENAb overnight at4 °C. The
bond complex was washed with cold lysis buffer, and 40 l of
the immunoprecipitated complex was loaded on a 4–20% SDS-
PAGE gel (Bio-Rad). After electrophoresis, the proteins were
revealed with Ab against PTEN (Santa Cruz; dilution 1:1000) or
GSH-protein complexes (Virogen, Watertown, MA).
Measurement of gcl and Cytokine Gene Expression—NR8383
cells were cultured in 60-mm Petri dishes and pretreated for 30
min with PD98059 (10M), LY294002 (50M), or wortmannin
(100 nM), followed byATP (3mM), BzATP (1mM), UTP (1mM),
ADP (0.4 mM), or control buffer for 5 min. The cells were then
centrifuged at 600 g at 4 °C for 10 min. When the cells were
pretreatedwith oxATP (0.3mM), the timeof incubationwas 2 h.
After centrifuging the cells, the RNA extraction was per-
formedwithRNEasyMinikit (250) fromQiagen (Valencia, CA),
following the manufacturer’s instructions, with an additional
step where 1 unit/l of RNase-free DNase (Fisher, Lafayette,
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CO) was added for 15 min after cell lysis. The reverse tran-
scriptase assay was performed using TaqMan-Reverse Tran-
scription Reagents (Applied Biosystem, Foster City, CA) with a
final volume of 40 l. The reaction cycle was performed on a
Eppendorf Termocycler for 45 min (25 °C for 10 min; 48 °C for
30min; 95 °C for 5min). Approximately 1g of cDNAwas used
for a real-timePCRusing primers specific for gclc and gclm. The
reaction was performed using SYBR Green Jump StartTM, Taq
Ready MixTM for quantitative PCR (Sigma). The reverse tran-
scriptase-PCR was performed on a3000 Stratagene Thermo-
cycler with a pre-heating cycle for 10min at 95 °C and 50 cycles,
then 95 °C for 25 s, 60 °C for 40 s, and 70 °C for 40 s.
The sequences of the gclc primers were: 5-ATGGAGGTA-
CAGTTGACAGAC-3, sense; and 5-ACGGCGTTGCCACC-
TTTGCA-3, antisense. For gclm, the primers were: 5-GCTG-
TACCAGTGGGCACAG-3, sense; and 5-GGCTTCAATGT-
CAGGGATGC-3, antisense. The il-18 primers were: 5-ATA-
TCGACCGAACAGCCAAC-3, sense; and 3-TAGGGTCAC-
AGCCAGTCCTC-5, antisense. As a control gene, we used
gapdh: 5-ACCCCCAATGTATCCGTTGT-3, sense; and 5-
TACTCCTTGGAGGCCATGT-3, antisense.
Measurement of Caspase-1 Activity by FACS—Caspase-1
activity wasmeasured in NR8383 cells using a caspase assay kit,
carboxyfluorescein Flica (Immunochemistry Technologies,
Bloomington, MN). In brief, 106 cells were incubated with dif-
ferent agonists or inhibitors followed by addition of the
caspase-1 fluorigenic substrate, FAM-VAD-fmk (20 M). As a
control for specificity, cells were also incubated with the
caspase-1 inhibitor, Z-YVAD-fmk, before adding FAM-VAD-
fmk. Fluorescence was measured using the Guava EasyCite.
Quantification of Cytokine Release—Ten million NR8383
cells were primed with 1 g/ml LPS for 2 h at 37 °C, and then
treated with 2 M DPI for 10 min, 50 M Z-YVAD-fmk for 30
min, or LY294002 for 10 min. Finally, the cells were stimulated
with 3 mM ATP or control buffer for 6 h. The cells were then
spun down and the supernatant collected. The ELISA analysis
of the supernatant was performed following themanufacturer’s
protocol for IL-18 (BIOSOURCE, Carlsbad, CA) and IL-1
(Pierce Biotechnology).
Statistical Analysis—The statistical analysis was performed
usingGraphPad InsTat software (GraphPadSoftware Inc., version
4.0) by Tukey test and was considered significant at p 0.05.
RESULTS
Extracellular ATP Induces ROS Production in Primary
Macrophages—Stimulation of primary rat microglia with the
P2X7 agonist, BzATP, leads to release of large amounts of
superoxide (23). To determine whether stimulation of primary
alveolar macrophages with ATP may also result in production
of ROS, macrophages were preincubated with the ROS-sensi-
tive dye, DCF, before treating with 3 mM ATP for 5 min. ATP
treatment caused the fluorescence of DCF to increase dramat-
ically, as measured by FACS, compared with background con-
trols (Fig. 1A). A comparable increase in fluorescence was
achieved by treating macrophages with 1 mM H2O2, and the
ATP-induced increase in ROS levels could be inhibited by
N-acetylcysteine (NAC) (Fig. 1A).
FIGURE 1. ATP induces ROS production inmacrophages. A, left, alveolar
macrophages were preincubated with an ROS-sensitive dye, DCF (5 M),
for 5 min, before treating with 3 mM ATP for another 5 min at 37 °C.
Enhancement in DCF fluorescence was measured immediately in a FACS,
which showed a large increase in fluorescence in ATP-treated macro-
phages, compared with DCF-labeled untreated controls. A, right, DCF flu-
orescence was quantified as the mean fluorescence measured by FACS.
Preincubation of macrophages with 25 mM NAC for 5 min before ATP
treatment abrogated the increase in ROS production. As a positive con-
trol, maximal ROS production was measured when untreated macro-
phages were incubated with 1 mM H2O2 for 5 min. p  0.001 for cells
treated with ATP, compared with cells treated with control buffer, or cells
treated with ATP with NAC. B, macrophages were preincubated with DCF
and then treatedwith control buffer (left) or 3mMATP (right) for 5min, and
visualized immediately with a fluorescence microscope. Phase-contrast
microscopy (top panels) does not show obviousmorphological changes in
macrophages due to ATP treatment. Green fluorescence (bottom panels)
was emitted from cells that had been treated with ATP (right, bottom) but
not from untreated controls (left, bottom). C, ROS production wasmaximal
after a 5-min incubationwith 3mMATP, and returned to basal levels within
15 min, as measured by FACS of DCF-labeled cells. All experiments were
performed in triplicate at least 3 times on separate days. The values show
averages and S.D. from 3 samples of a representative experiment.
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ATP-induced ROS production was also confirmed by view-
ing ATP-treated macrophages by fluorescence microscopy
(Fig. 1B). Furthermore, the increase in ROS levels was transient.
By FACS, ROS production was detectable within 0.5 min of
ATP stimulation, rose to maximal levels within 5min, and sub-
sided to basal levels by 15 min (Fig. 1C).
Ligation of P2X7 and Other Purinergic Receptors Leads to
ROS Production—Besides expressing the purinergic receptor,
P2X7, rat alveolarmacrophages express other purinergic recep-
tors, which can be stimulated by ATP, ADP, and UTP (24, 25).
All of these nucleotides, including UDP, can promote high lev-
els of ROS production (Fig. 2A). At least part of the ATP-medi-
ated response is due to the P2X7 receptor, as it can be blocked
partially by pretreatment with the irreversible P2X7 antagonist,
oxATP, and can be stimulated with the P2X7 agonist, BzATP
(26) (Fig. 2, B and C). As incubation with extracellular ADP,
UDP, and UTP can also induce ROS production, these results
suggest that ligation of P2X7 ligation and other purinergic
receptors, possibly P2X4, P2Y1, P2Y2, P2Y6, or P2Y12 (24), can
all lead to activation of enzymes that result in ROS production.
Ligation of Purinergic Receptors Leads to Activation of the
PI3K Pathway—Extracellular ATP can activate PI3K in macro-
phages and other cell types (6, 8, 27). In many cell types, PI3K
phosphorylates and activates the downstream Ser/Thr kinase,
Akt/PKB, which promotes survival or controls metabolism
through phosphorylation of multiple targets (28). Although
oxidants are known to stimulate the PI3K/Akt pathway (29, 30),
the mechanism linking P2 receptor ligation with PI3K activa-
tion had not been elucidated. We therefore explored the possi-
bility that ATP-mediated ROS production could activate the
PI3Kpathway in alveolarmacrophages, bymeasuring phospho-
rylation of Akt by immunoblots using Ab against a phosphoryl-
ated residue of Akt (residue Thr308) that leads to Akt activation
in different cell types. As shown in Fig. 3, a short incubation of
FIGURE 2. Ligation of several purinergic receptors can stimulate ROS pro-
duction inmacrophages.A, incubationofDCF-labeledmacrophageswith3mM
ATP, 3mMUTP, 0.4mMADP, or 0.1mMUDP results in an increase in ROS levels in
macrophages, as measured by FACS of DCF-stained macrophages. p 0.01
for cells treated with ATP, compared with cells treated with control buffer.
B, preincubation of macrophages with 0.3 mM of the P2X7 antagonist,
oxATP, for 2 h inhibits partially ATP-mediated ROS production due to treat-
ment with 3mM ATP for 5min. p 0.05 for cells treated with oxATP and ATP,
compared with cells treated with ATP. C, incubation with 1 mM of the P2X7
agonist, BzATP, for 5 min induces as much ROS production as 3 mM ATP. p
0.001 for cells treated with BzATP, compared with cells treated with control
buffer. The values show averages and S.D. from 3 samples of a representative
experiment, and represent results obtained fromat least three representative
experiments.
FIGURE 3. Treatment of macrophages with ATP results in ROS-dependent
PI3KactivationandAktphosphorylation.Macrophageswerepretreated for 5
min with 25 mM NAC or 50 M of the PI3K inhibitor, LY294002, for 5 min, and
incubated for 5 min with 3 mM ATP. Akt phosphorylation was determined by
Westernblot,usinganAbrecognizingAktphosphorylatedonresidueThr308.The
Westernblot is representativeof threeexperimentsperformedonseparatedays.
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macrophages with ATP caused Akt phosphorylation to
increase significantly, consistent with previous reports in mac-
rophages and astrocytes (8, 27). The increase in Akt phospho-
rylation could be inhibited by co-treatment of macrophages
with NAC (Fig. 3, lane 3), suggesting that ATP-induced ROS
production leads to Akt phosphorylation. In addition, ATP-
induced Akt phosphorylation was blocked almost completely
by pre-treatment of macrophages with the PI3K inhibitor,
LY294002 (Fig. 3, lane 4), implying that ATP-mediated ROS
production results in PI3K activation and subsequently to Akt
phosphorylation/activation.
ROS-dependent PI3K Activation Leads to ERK1/2
Phosphorylation—Recent studies have shown that ATP treat-
ment of thymocytes and macrophages results in phosphoryla-
tion of ERK1/2, which is downstream from PI3K activation (6,
8). To investigate whether ROS-dependent PI3K activation can
in turn lead to ERK1/2 activation, we stimulated alveolar mac-
rophages with ATP in the presence of antioxidants or PI3K
inhibitors, andmeasuredERK1/2 phosphorylation by immuno-
blot, using Ab against phosphorylated residues of ERK1/2 (res-
idues Thr202 and Tyr204) that lead to ERK1/2 activation (31).
Thus, ATP stimulation of macrophages led to ERK1/2 phos-
phorylation within 1 min, consistent with the time course of
ROS production after ATP treatment (Fig. 1C), which could be
inhibited byNAC and the ERK1/2 inhibitor, PD98056 (Fig. 4A).
Interestingly, the time course of ERK1/2 phosphorylation was
also similar to Akt phosphorylation (Fig. 4A), although Akt
phosphorylation subsided after 10 min, as observed for ATP-
induced ROS production (Fig. 1C). ERK1/2 phosphorylation
was confirmed bymeasuring stainingwithAb against phospho-
rylated ERK1/2 by FACS. Short ATP treatment led to ERK1/2
phosphorylation, which could be inhibited partially by the PI3K
inhibitors, wortmannin (Fig. 4, B andC) or LY294002 (Fig. 4C),
or the ERK1/2 inhibitor, PD98056 (Fig. 4, B and C). Again,
ERK1/2 phosphorylation was inhibited by co-treatment with
NAC (not shown). Taken together, the results imply that ATP
treatment leads to ROS production, which activates PI3K, and
PI3K in turn activates Akt and ERK1/2.
ATP-mediated Glutathionylation of PTEN Correlates with
Activation of the PI3K Pathway—The phosphatase, PTEN,
removes the 3-phosphate of phosphatidylinositol 3,4,5-
triphosphate, thus inhibiting PI3K signaling. Previous studies
have revealed that PTEN can be inhibited reversibly by H2O2
(32, 33). Moreover, oxidized cysteines can then form a disulfide
bond with glutathione (GSH), the main antioxidant present in
the cell cytosol. A number of signaling proteins have recently
been shown to undergo glutathionylation, including protein-
tyrosine phosphatases and transcription factors (34–38). But as
there are no known examples for activating kinases through
glutathionylation, we reasoned that inactivation of PTEN
through glutathionylation could result in de facto activation of
the PI3K pathway.
To test this hypothesis, macrophages were treated with ATP,
lysed in a GSH-rich lysis buffer, and proteins were then immu-
noprecipitated with PTEN-conjugated beads and submitted to
electrophoresis. Immunoblotting with an Ab against GSH
revealed that a sizable fraction of PTEN exists in a monomeric
form that can be recognized by the anti-GSH Ab even in
untreated macrophages, with a smaller fraction of PTEN being
found in a high molecular weight complex (Fig. 5A). But the
amount of PTEN in both themonomeric glutathionylated form
and in the high molecular weight complex increased signifi-
cantly after a 3-min incubation with ATP (Fig. 5A). Treatment
of the immunoprecipitate with the reducing agent, dithiothre-
itol, before electrophoresis resulted in disappearance of both
themonomeric andmultimeric PTEN (Fig. 5A), demonstrating
that theAb recognized only the glutathionylated formof PTEN.
FIGURE 4. ATP-dependent ROS production and PI3K activation are
upstream from ERK1/2 phosphorylation. A, macrophages were incubated
with 3 mM ATP, and cells were lysed at different times after the addition of
ATP. ERK1/2 phosphorylation was determined byWestern blot, probingwith
an Ab recognizing ERK1/2 phosphorylated on residues Thr202 and Tyr204. Akt
phosphorylation was measured with an Ab recognizing Akt phosphorylated
on residue Thr308. The Western blot is representative of three experiments
performed on separate days. B, ERK1/2 phosphorylation was confirmed by
FACS. Macrophages were pretreated for 5minwith control buffer (left panel),
1M of the PI3K inhibitor, wortmannin (middle panel), or 10M of the ERK1/2
inhibitor, PD98056 (right panel), for 5min, and incubated for 5minwith 3mM
ATP. ERK1/2 phosphorylation was measured by FACS, after incubating per-
meabilized cells with the Ab recognizing phosphorylated ERK1/2. C, ERK1/2
phosphorylation was quantified as the mean fluorescence measured by
FACS. Preincubation of macrophages with the ERK1/2 inhibitor, PD98056, or
the PI3K inhibitors, wortmannin or LY294002, for 5min before ATP treatment
decreased significantly the extent of ERK1/2 phosphorylation. p 0.001 for
cells treatedwithwortmanninandATP, comparedwith cells treatedwithATP.
The results are representative of at least two experiments performed on sep-
arate days.
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Reprobing the same membrane with an Ab against PTEN
verified the presence of PTEN (60 kDa) in both the treated and
untreated macrophages (Fig. 5B). The anti-PTEN Ab also con-
firmed the presence of PTEN in the high molecular weight
complex, whose levels increased after the 3-min incubation
with ATP (Fig. 5B). As expected, dithiothreitol dissociated
PTEN from the multimeric complex, without affecting the pres-
ence of the monomeric PTEN (Fig. 5B). Thus, ATP-dependent
glutathionylation of PTEN correlates with ATP-dependent acti-
vation of PI3K and is likely to contribute to activation of the
PI3K pathway.
ROS Production Results in a PI3K-dependent Redox Response
through Expression ofGenes Involved inGSHSynthesis—GSH is
the most abundant intracellular nonprotein thiol and most
important antioxidant in the cytosol. GSH is synthesized
through the sequential action of glutamate cysteine ligase
(GCL) and glutathione synthase (GS) (39, 40). The rate-limiting
enzyme in GSH synthesis, GCL, is composed of two subunits,
the catalytic (GCLC) andmodulatory (GCLM) subunits, which
are encoded by separate genes, gclc and gclm, that are regulated
independently in response of oxidative stress.
As GCL plays a key role in resistance to ROS-mediated oxi-
dative stress (41, 42), we determinedwhether ATP treatment of
macrophages may affect gcl expression by real-time PCR, using
primers specific for gclc and gclm. Thus, short incubation of
macrophages with ATP led to significant up-regulation of both
the gclc and gclm genes, whereas smaller up-regulation was
observed when macrophages were stimulated with UTP or
ADP (Fig. 6A). Incubation with the P2X7 agonist, BzATP, also
resulted in a large increase in gclc and gclm expression, whereas
the antagonist oxATP inhibited ATP-induced gclm and gclc
up-regulation (not shown), suggesting that ligation of several
purinergic receptors, including P2X7,may stimulate gcl up-reg-
ulation. The expression of gclwas similar to control levels when
ATP-treated macrophages were also treated with catalase (not
shown), which converts H2O2 produced on the outside of cells
into water and oxygen, implying that ATP-mediatedH2O2 pro-
FIGURE 5. ATP-dependent ROS production induces glutathionylation of
PTEN. Macrophages were pretreated for 5 min with control buffer or 3 mM
ATP for 1 min. Cells were lysed, and the proteins were immunoprecipitated
overnight with PTEN-conjugated beads. A, the extent of glutathionylation
was determined byWestern blot, using an Ab recognizing GSH. The anti-GSH
Ab revealed thepresenceof immunoprecipitatedproteinboth as amonomer
corresponding to the molecular mass of PTEN (60 kDa) or a larger complex
(200 kDa). The level of glutathionylation of PTEN in both monomeric and
multimeric forms increases after ATP stimulation ofmacrophages. Treatment
of the immunoprecipitatewith the reducing agent dithiothreitol before elec-
trophoresis dissociatesGSH fromall proteins.B, the resultswere confirmedby
reprobing the same membrane with an Ab recognizing total PTEN. The anti-
PTEN Ab also revealed the presence of PTEN in monomers and a larger com-
plex. Macrophage stimulation with ATP causes the amount of PTEN in the
larger complex to increase slightly. Treatment with the reducing agent dithi-
othreitol causes PTEN to dissociate from the larger complex. The Western
blots are representative of two experiments performed on separate days.
FIGURE 6. Stimulation of macrophages with ATP results in PI3K- and
ERK1/2-dependent up-regulation of genes involved in GSH synthesis.
A, incubation of macrophages with 3mM ATP, 3 mM UTP, or 0.4 mM ADP for
20 min, followed by an additional 6 h in the absence of nucleotides results
in an increased expression of gclc and gclm, as measured by real-time PCR.
p  0.001 for gclm of cells treated with ATP, compared with cells treated
with control buffer; and p 0.01 for gclm of cells treated with ADP, com-
pared with cells treated with control buffer. B, macrophages were pre-
treated for 5 min with the PI3K inhibitors, LY294002 (50 M), or the ERK1/2
inhibitor, PD98056 (10 M), for 5 min, and then incubated for 5 min with 3
mM ATP. Expression of gclm and gclc was measured by real-time PCR. p
0.001 for gclm of cells treated with ATP, compared with cells treated with
ATP or either LY294002 or PD98056. The results are representative of at
least three experiments performed on separate days.
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duction is responsible for regulation of gclc and gclm
expression.
Given the effect of ATP-mediated ROS production on PI3K
activation, we then investigatedwhether the PI3K pathwaymay
influence gcl expression. Both the PI3K inhibitors, LY294002
and wortmannin (shown for LY294002 in Fig. 6B), and the
ERK1/2 inhibitor, PD98056 (Fig. 6B), blocked ATP-dependent
gcl up-regulation. Taken together, these results suggest that
ATP ligation of P2X7 results in an increase in ROS levels, which
activate PI3K and subsequently ERK1/2, which in turn regu-
lates the oxidative stress response of the cell.
Extracellular ATP Leads to Cytokine Secretion through a Path-
way Involving ERK1/2-dependent Caspase-1 Activation—Extra-
cellular ATP stimulates secretion of the key proinflammatory
cytokines, IL-1 and IL-18, through a pathway requiring the
presence of P2X7 (2). P2X7 ligation by itself does not lead to
IL-1 or IL-18 transcription or translation, but after macro-
phage stimulation of receptors such as the TLR, P2X7 ligation
by ATP results in activation of caspase-1 and secretion of the
mature form of both cytokines. Recently it was shown that an
inflammasome is required for ATP-dependent IL-1 and IL-18
secretion (10), but a molecular pathway linking P2X7 ligation
and the inflammasome was not identified. We therefore
explored the possibility that ATP-mediated ROS production
may play a role in caspase-1 activation and cytokine secretion.
Caspase-1 activation was quantified bymeasuring binding to
cells of a fluorescently labeled caspase inhibitor by FACS. As
measured by real-time PCR, ATP treatment, in the absence of
TLR ligands, had no effect on transcription for IL-18 (not
shown), in agreement with previous studies on the lack of effect
of ATP alone on IL-1 transcription (2). However, ATP treat-
ment by itself results in caspase activation (Fig. 7A). Caspase
activation was also inhibited by pretreating the cells with
the irreversible caspase-1 inhibitor, Z-YVAD-fmk, before
incubation with ATP (not shown), confirming that caspase-1
was activated by ATP. Importantly, ATP-mediated caspase-1
activation was inhibited strongly when macrophages were co-
incubated with DPI (Fig. 7A), a flavoprotein inhibitor of NADPH
oxidase, consistentwith the conclusion thatATP-dependent ROS
production is responsible for caspase-1 activation.
To determine whether ROS production is sufficient for
caspase-1 activation, we then evaluatedwhether the PI3K path-
way may be involved. To examine the role of a downstream
mediator in the pathway, wemeasured the effect of the ERK1/2
inhibitor on caspase-1 activation. The ERK1/2 inhibitor,
PD98056, blocked essentially all of the ATP-mediated
caspase-1 activation (Fig. 7B). Conversely, the irreversible
caspase-1 inhibitor had no effect on ATP-dependent ROS pro-
duction (not shown). These results demonstrate that ATP-me-
diated ROS production leads to ERK1/2 activation, which in
turn regulates activation of the inflammasome.
Because ATP alone cannot induce synthesis of cytokines (2),
the role of ROSproduction and caspase-1 activation in cytokine
secretion was then addressed usingmacrophages that had been
primed with the TLR4 ligand, LPS, before stimulating the mac-
rophages with ATP. IL-1 and IL-18 secretion was quantified
by ELISA. Incubation of primed macrophages with ATP led to
secretion of both IL-1 and IL-18, which in both cases could be
inhibited by pretreatment with DPI (shown for IL-1 in Fig. 8),
consistent with our observations that DPI blocks caspase-1
activation (Fig. 7A). Cytokine secretion was also inhibited by
preincubation with the PI3K inhibitor, LY294002, or the
caspase-1 inhibitor, Z-YVAD-fmk (Fig. 8). Thus, ATP-medi-
ated ROS production in LPS-primed macrophages leads to
FIGURE 7. ATP-dependent ROS production and ERK1/2 activation are
upstream from caspase-1 activation. A, macrophages were stained with
the fluorescent caspase substrate, FAM-VAD-fmk, pretreated for 10 min with
the redox inhibitor, DPI (2 M), and then incubated for 6.5 or 12 h with 3 mM
ATP. Caspase-1wasmeasuredby FACS. The specificity of caspase-1 activation
was verified by pretreating the stained cells with the irreversible caspase-1
inhibitor, Z-YVAD-fmk. p 0.001 for cells treated with DPI and ATP for 12 h,
compared with cells treated with ATP for 12 h. B, stained macrophages were
pretreated for 5 min with 10 M of the ERK1/2 inhibitor, PD98056, for 5 min,
before incubation for 5 min with 3 mM ATP. p  0.001 for cells treated with
PD98056 and ATP for 6.5 or 12 h, comparedwith cells treatedwith ATP alone.
The values show averages and S.D. from experiments performed in triplicate,
and represent results obtained from at least two representative experiments.
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ERK1/2 activation, which is upstream from caspase-1 activa-
tion and cytokine secretion.
DISCUSSION
Until recently, the production of H2O2 was studied primarily
in macrophages and neutrophils. These cells use the NADPH
oxidase complex (Nox2) in the plasma membrane to generate
H2O2. The primary purpose of the respiratory burst in neutro-
phils is to kill internalized pathogens; however, in alveolarmac-
rophages, a signaling role for H2O2 produced by the respiratory
burst may be more important (18). In phagocytes, activation of
the immune cells by pathogens leads to assembly of the Nox
complex at the plasma membrane, which releases superoxide
into the phagosome. Superoxide dismutation then results in
production ofH2O2.Nonphagocytic cells also express the func-
tional homologues of the Nox catalytic subunit (43), and can
generate H2O2 at the plasma membrane following stimulation
with cytokines and growth factors (44).
We show here that stimulation of alveolarmacrophages with
ATP and other extracellular nucleotides leads to transient pro-
duction of high levels of ROS. The effects of the agonist BzATP
and the antagonist oxATP suggest that P2X7 ligation is respon-
sible for much of the activity. Although the pathway coupling
purinergic receptor ligation with ROS generation remains
unknown, it is likely that the Nox complex is activated at the
level of the plasmamembrane. LocalizedNox assembly has pre-
viously been reported in lipid rafts in activated microglia and
HL-60 cells and in focal complexes in migrating endothelial
cells (45, 46), and could also take place near ligated P2X7, which
has been found to localize in lipid rafts in T cells and cells from
submandibular glands (47, 48).
What could be the trigger for Nox assembly? Potassium
depletion due to ionophore or ATP treatment leads to an influx
of Ca2 and the activation of phosphatidylcholine-specific
phospholipase C and calcium-independent and -dependent
phospholipase A2 (PLA2) (49, 50). Calcium-independent PLA2
(iPLA2) stimulates the colocalization of caspase-1 and pro-
IL-1 in secretory lysosomes, which could favor caspase-1 acti-
vation and pro-IL-1 cleavage and perhaps its subsequent
shedding (10, 51). It has been proposed that Nalp3 may also
respond to cytosolic lipids such as arachidonic acid and lyso-
phospholipids generated by iPLA2 (10). Phospholipase-gener-
ated signals in ATP-treated macrophages may also synergize
with elevated cytosolic Ca2 in stimulating ROS production, as
Ca2 levels or iPLA2 activity in various cell types can modulate
ROS production (52–54). Conversely, elevated ROS levels can
activate iPLA2 or trigger Ca2 fluxes (55, 56), suggesting that
P2X7-dependent inflammasome activation could conceivably
involve a cooperative loop between ROS generation, Ca2
fluxes, and iPLA2 activation.
ROS is involved in diverse receptor systems, including tumor
necrosis factor-, epidermal growth factor, platelet-derived
growth factor, the T and B cell receptors, and insulin (17, 52,
57–60). Signal activation is often thought to occur through
ROS-mediated inhibition of protein-tyrosine phosphatases,
which shifts the equilibrium in favor of kinase activation. An
essential cysteine in the active site of protein-tyrosine phospha-
tases has been identified as target for oxidation by H2O2, which
can then undergo reversible glutathionylation (35–37). Previ-
ous studies have shown that oxidative inactivation of phospha-
tases leads to sustained activation of the corresponding kinases
(44). As activation of kinases through glutathionylation has not
been reported, we investigated the possibility that the cognate
phosphatase, PTEN, could be inactivated. In fact, PTEN is glu-
tathionylated soon after ATP stimulation ofmacrophages. ROS
production and PTEN glutathionylation in ATP-stimulated
macrophages could thereby shift the balance in favor of PI3K,
which leads in turn to phosphorylation of Akt. In agreement
with previous studies (5, 6), we find that ERK1/2 is also acti-
vated in ATP-treated cells, although the mechanism for activa-
tion of the PI3K pathway was not identified.
An important feature of any signaling pathway is reversibil-
ity. For ROS to regulate PTEN reversibly, it is critical to prevent
oxidation of the active site Cys of PTEN beyond sulfenic acid
(S-OH). The enzyme is protected against further, irreversible
oxidation by reaction with GSH to form the mixed disulfide
(44). Glutathionylation of PTEN leads to formation of high
molecular weight oligomers, which can be reversed in lysed
cells by incubation with a reducing agent. Treatment of cells
with oxidants or the proinflammatory cytokines, tumor necro-
sis factor- and IL-1, causes an initial depletion of GSH, fol-
lowed by recovery and increased synthesis of GSH (39). The
rate-limiting enzyme in GSH synthesis is GCL, and its expres-
sion is regulated by several transcription factor binding sites,
such as AP-1 and antioxidant response elements, in response to
oxidants and inflammatory stimuli (39), thus providing an
adaptive mechanism to protect the cells during subsequent
proinflammatory or oxidant stress. Similarly, we find that gcl
expression increases following treatmentofmacrophageswith the
proinflammatorymediator,ATP.Theup-regulationrequiresboth
ROS production and activation of the PI3K pathway.
Unexpectedly, we found that ATP-mediated, ROS-depend-
ent PI3K activation is also involved in activation of caspase-1
and processing of IL-1 and IL-18. The Nalp3 inflammasome
can be activated by stimuli as diverse as ATP, K ionophores,
bacterial toxins, and uric acid crystals (10, 11). It will be intrigu-
FIGURE 8. ATP stimulation of macrophages leads to IL-1 secretion
through a pathway requiring ROS production and PI3K activation.
Macrophages were primed with 1 g/ml LPS for 2 h at 37 °C, before treating
the macrophages with the caspase-1 inhibitor, Z-YVAD-fmk (50 M) for 30
min, DPI (2M) for 10min, or LY294002 (50M) for 10min. The cellswere then
stimulated with 3 mM ATP for 6 h. Secretion of IL-1was measured by ELISA.
p 0.001 for cells treated with ATP and Z-YVAD-fmk, DPI, or LY294002, com-
paredwith cells treatedwithATPalone. The experimentwasperformed twice
in duplicate, and the results represent the average and S.D.
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ing to determine whether any of the cell signaling pathways
initiated by stimuli other than ATP may also converge on the
inflammasome via ROS.
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